Our study establishes a link between the dosage effect of MX1 and the AP-1 mediated transcriptional profile in I-IFN driven DS pathogenesis, thereby providing a potential mechanism for the involvement of MX1 in the dosage effect observed in DS. The gene discussed is JUN; the disease is Dravet syndrome.